Page 38 - Service Testing News Today

The stock rose, as did shares of Biogen, which is developing a separate treatment. Lilly said its experimental drug slowed the cognitive decline of early-stage patients.

Nation’s emergency-use approval comes despite trial results placing the shot at 65.3%, the low end of efficacy range.

First off, Twitter (TWTR) stock fell 6.4% after banning President Donald Trump’s account. The President has roughly 88 million followers and analyst Crag Huber at Huber Research Partners tells Barron’s some are assuming roughly 12 million to 15 million daily active users leave the platform. That’s about 6% to 8% of Twitter’s total 187 million daily active users, potentially justifying the stock’s reaction, which doesn’t necessarily account for any changes in profit margins....

Dreamstime BioMarin Pharmaceutical has been running the world’s largest clinical trial of a gene therapy in hopes of sparing hemophilia patients from frequent bleeding and chronic drug infusions. But the company suffered a rebuke last August, when U.S. regulators demanded a lengthier study before approval would be considered. On Sunday, BioMarin (ticker: BMRN) released data on the first year of the continuing study of its Roctavian therapy. The data looked good. In 112 part...

TIC Services Market revenue to cross USD 240 Bn by 2026: Global Market Insights, Inc. The Europe testing, inspection and certification services market is predicted to expand at a CAGR of more than 4% during 2020 to 2026 owing to the increasing demand for TIC services by automotive manufacturers in European region. Selbyville, Delaware, Dec. 17, 2020 (GLOBE NEWSWIRE) — According to latest report “Testing, Inspection and Certification Services Market by Service (Testing, Inspection, Certifi...